EyePoint Pharmaceuticals, Inc. Director Nancy Lurker is set to sell 5,044 shares of common stock on 01/23/2024, as per the latest SEC filings. The shares to be sold have an aggregate market value of approximately $125,949.69. The securities were acquired through open market purchases and stock options between October 2019 and February 2020. This planned sale follows a previous transaction where Lurker sold 20,000 shares for a total gross proceed of $415,164 on 12/04/2023.

EyePoint Pharmaceuticals, Inc. Director Nancy Lurker is set to sell 5,044 shares of common stock on 01/23/2024, as per the latest SEC filings. The shares to be sold have an aggregate market value of approximately $125,949.69. The securities were acquired through open market purchases and stock options between October 2019 and February 2020. This planned sale follows a previous transaction where Lurker sold 20,000 shares for a total gross proceed of $415,164 on 12/04/2023.